July 13, 2016
CTI Clinical Trial & Consulting Services Announces Five Abstracts Presented at ISPOR
FOR IMMEDIATE RELEASE [Cincinnati, OH ~ July 13, 2016]
CTI Clinical Trial and Consulting Services (CTI) announces that five abstracts were presented at the International Society for Pharmacoeconomics Outcomes Research (ISPOR) early this summer on behalf of Cardiovascular Systems, Inc. (CSI360), a large medical device company.
“This was an incredible series of projects and our team really enjoyed working with Cardiovascular Systems. We shared similar goals and timelines to develop an important research platform which generated evidence that could significantly improve the outcomes of patients with peripheral artery disease and potentially salvage limbs that would be amputated per standard practice.” says Lynn Fallon, CTI President.
Harry Kotlarz, Cardiovascular Systems, stated, “I don’t ever recall in my career where we formulated a series of study hypotheses and in 5 months, had 5 abstracts delivered and submitted, only to be followed by 5 acceptances! It is unheard of…and is the result of a talented and hard-working and visionary team – I am humbled to be a part of it – thank you!” The senior director also added, “I am most excited because our evidence generation strategy is paving the way towards an even greater awareness of PAD (Peripheral Artery Disease) and limb salvage opportunities for the patients we serve.”
The list of abstracts presented included:
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com